TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
At an American Academy of Dermatology meeting, researchers discussed a widening range of treatment strategies for chronic spontaneous urticaria (CSU), including BTK inhibition, IL-4 receptor blockade and c-KIT targeting. Brian Kim also cited phase III findings for remibrutinib in three forms of chronic inducible urticaria, but the supplied report does not provide trial results or establish when those findings could change care.
Researchers at an American Academy of Dermatology meeting discussed new and emerging treatment approaches for chronic spontaneous urticaria (CSU), including BTK inhibition, IL-4 receptor blockade and c-KIT targeting. In a video recorded after the April meeting, Mount Sinai dermatologist Brian Kim also pointed to reported phase III data for remibrutinib in three forms of chronic inducible urticaria (CIndU), broadening the research conversation beyond CSU.
Kim, a professor of dermatology and vice chair of research at the Icahn School of Medicine at Mount Sinai, identified remibrutinib as a prominent topic. The drug, marketed as Rhapsido, is a BTK inhibitor that the report describes as recently approved for CSU. Kim said phase III data had also been reported in CIndU involving dermatographism, cold urticaria and cholinergic urticaria. The brief report does not give the studies’ results, effect sizes or safety findings.
The discussion also covered dupilumab (Dupixent), which blocks the IL-4 receptor, and barzolvolimab, a c-KIT inhibitor. Kim said barzolvolimab may inhibit and possibly deplete mast cells. He disclosed that he co-founded Alys Pharma, which is developing a c-KIT inhibitor using a bispecific strategy intended to block c-KIT on mast cells. That company-related work is a separate investigational approach, not evidence in the report that it is approved or established treatment.
The account presents a range of targets rather than a head-to-head comparison. It does not provide trial protocols, publication details, regulatory status for each approach, or a timeline for possible treatment decisions. Claims about promise and future prospects are attributed to Kim; they should not be read as proof that every drug works for every patient or that a new standard of care has been set.
More Targets, More Treatment Questions
The discussion matters because it points to several biological targets being pursued for persistent hives, rather than a single treatment strategy. CSU occurs without a consistent external trigger, while CIndU is associated with particular stimuli; the report’s mention of three CIndU types suggests researchers are examining whether therapies may have roles across distinct forms of the condition.
For patients and clinicians, additional approaches could eventually broaden choices if studies establish benefit, safety and appropriate use. But the meeting coverage alone does not show that the investigational or newly discussed strategies are suitable alternatives for an individual patient. Trial results and regulatory decisions will determine whether the research translates into routine care.
chronic hives treatment medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From CSU to Inducible Hives
The AAD session described by Kim was only the second CSU-focused session at the association’s meeting, following an earlier one. The meeting took place in Denver, Colorado, and the video was recorded afterward in April; MedPage Today published its report on October 8, 2026. The timing matters: the article is a meeting recap, not a newly released trial paper.
Its account groups the approaches by target: IL-4 receptor blockade with dupilumab, BTK inhibition with remibrutinib, and c-KIT targeting with barzolvolimab and a separate bispecific strategy described by Kim. The source identifies remibrutinib as recently approved for CSU, but does not specify the approval date or provide enough detail to verify the scope of the authorization independently.
“This is a unique drug that actually not only inhibits mast cells, but probably depletes mast cells as well.”
— Brian Kim, describing barzolvolimab
As an affiliate, we earn on qualifying purchases.
Evidence and Approval Details Pending
The report offers no numerical outcomes for the remibrutinib phase III studies, including response rates, safety data, study duration or comparisons with other treatments. It also does not state whether the results have been published in full or reviewed by regulators. The phrase “great phase III data” is Kim’s characterization in the video.
It remains unclear from this account what evidence supports use of each drug in each urticaria subtype, how the approaches compare, and when the c-KIT strategies might reach later-stage testing or regulatory review. The source also does not provide details of the bispecific candidate’s development stage. No conclusions about an individual’s care can be drawn from this meeting recap.
As an affiliate, we earn on qualifying purchases.
Trial Results Will Set the Pace
The next useful milestones are fuller reporting of remibrutinib’s phase III findings across dermatographism, cold urticaria and cholinergic urticaria, including efficacy and safety results. Further clinical studies and regulatory updates would clarify whether those findings support use beyond CSU.
For dupilumab, barzolvolimab and the bispecific c-KIT candidate, readers will need additional trial data and clear development or approval updates. The meeting coverage does not announce a specific upcoming decision or date. Until those details emerge, the expanded landscape described by Kim is best understood as a mix of an approved CSU drug, discussed therapies and research approaches at different stages.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the main development in the report?
Meeting coverage described multiple targets under discussion for chronic spontaneous urticaria, and reported that remibrutinib had phase III data in three forms of chronic inducible urticaria. The source does not include detailed trial results.
Which drug is described as recently approved for CSU?
The report identifies remibrutinib, marketed as Rhapsido, as a recently approved BTK inhibitor for CSU. It does not give the approval date or further authorization details.
Which inducible-urticaria types were mentioned?
Kim cited studies involving dermatographism, cold urticaria and cholinergic urticaria. The article provides no response rates or other trial measurements for those groups.
Are all the therapies discussed established treatments?
No. The report describes remibrutinib as recently approved for CSU, discusses dupilumab and barzolvolimab, and mentions a bispecific c-KIT strategy being developed by Alys Pharma. It does not establish approval or routine use for every approach or condition discussed.
What remains unknown about the new data?
The source does not supply study results, safety findings, comparisons, publication details or regulatory timelines for the phase III CIndU data. Further reporting and clinical or regulatory updates are needed to clarify what the findings mean for care.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
